A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy

BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that retains the antitumor effects of trastuzumab while also delivering the cytotoxic antimicrotubule agent, DM1, directly to tumor cells that overexpress human epidermal growth factor receptor 2. The pharmacokinetic (PK) profil...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Principais autores: Ji, Dongmei, Shen, Weina, Zhang, Jian, Cao, Junning, Li, Wenhua, Lam, Lisa H., Wu, Fan, Wang, Bei, Li, Zao, Sun, Guofang, Hu, Xichun, Chen, Shang-Chiung
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2020
Assuntos:
5750
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7598804/
https://ncbi.nlm.nih.gov/pubmed/33126339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000022886
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados